About Omega Therapeutics:

Omega Therapeutics is a development-stage biotechnology company pioneering a new class of programmable, mRNA-encoded therapeutics to transform human medicine. The OMEGA Epigenomic Programming™ platform harnesses the power of epigenetics, the mechanism that controls gene expression and every aspect of an organism's life from cell genesis, growth and differentiation to cell death. The OMEGA platform enables control of fundamental epigenetic processes to correct the root cause of disease by returning aberrant gene expression to a normal range without altering native nucleic acid sequences. Omega’s engineered, modular, and programmable mRNA-encoded epigenetic medicines, Omega Epigenomic Controllers™, target specific intervention points amongst the thousands of validated novel DNA-sequence-based epigenomic targets we have mapped to tune single or multiple genes to treat and cure disease through Precision Genomic Control™. Omega is currently advancing a broad pipeline of development candidates spanning a range of disease areas, including oncology, regenerative medicine, multigenic diseases including immunology, and select monogenic diseases.

About the Role:

Omega Therapeutics, Inc. is seeking a Principal Scientist / Associate Director, Drug Product Analytical Development (commensurate with experience) to join our Drug Product Analytical Development team.  This leadership position will be responsible for leading analytical method development for Omega’s mRNA-based lipid nanoparticle drug product therapeutics from research to the clinic.  They will work closely with Research, Drug Substance Analytical Development, DS & DP Process Development, and Quality Control to develop novel release and characterization methods, transfer of methods to contract labs or contract manufacturing organizations for GMP testing, and drafting of CMC sections and supporting documents for regulatory filings.  They will manage all aspects of the drug product analytical development lab to ensure reliable internal testing is performed, including the management of methods, SOPs, protocols and method development reports.  We are looking for enthusiastic, detail oriented, and highly motivated individuals with a passion for bringing novel medicines to patients and who are comfortable working on a fast-paced scientific team.

Key Responsibilities:

  • Lead a group of scientists to fully develop analytical methods that robustly characterize our mRNA-based lipid nanoparticle drug products
  • Create analytical understanding to support robust clinical and ultimately commercial supply of all our platform products
  • Develop a team with the abilities manage testing of multiple programs and continually advance the technology
  • Design, execute, and document analytical method development in support of process development, product release, stability, and product characterization of mRNA therapies
  • Ensure standard operating procedures, analytical test methods, and analytical sampling plans meet the highest industry standard
  • Assure appropriate laboratory controls for sample management, data integrity, reagents, and equipment
  • Review and approve method development and qualification reports
  • Work with internal and external (CMO and CRO) laboratories to assure robust method development, transfer, and execution in GMP and GLP settings
  • Work cross-functionally and ensure a collaborative work environment with client groups, including Research, Process Development, Quality Control, and Manufacturing teams
  • Work cross functionally to develop phase-appropriate specifications for DP
  • Author, review and approve IND, IMPD, BLA and MAA sections; participate in scientific advice preparations and meetings

Required Qualifications:

  • Ph.D. in Analytical Chemistry, Biochemistry, Biology with 5+ years of industrial experience OR MS with 10+ years of industrial laboratory experience
  • Prior experience with mRNA and/or liposome/lipid nanoparticle (LNP) formulation characterization and release testing required; knowledge of drug product potency assays is preferred
  • Experience leading complex, multi-disciplinary projects and teams during biotech drug development
  • Advanced hands-on experience with various analytical techniques including UPLC/HPLC, Sequencing, ELISA, qPCR, Western blot, SDS page, particle size, and compendial test methods
  • Strong understanding of Design of Experiments (DOE) and QbD is a plus
  • Ability to lead a team of scientists to develop comprehensive analytical understanding of products in pre-clinical and clinical development
  • Experience preparing technical documents for internal distribution or inclusion in CMC or regulatory filings
  • Knowledge of QbD approaches to analytical method development including risk assessment, DOE, and statistical analysis
  • Ability to function efficiently and independently in a changing environment
  • Well organized and ability to coordinate testing for numerous clinical candidates at multiple contract sites
  • Demonstrated creativity and problem-solving skills
  • Excellent communication skills, both oral and written
  • Demonstrated ability in working with highly skilled teams in a fast paced, entrepreneurial and technical setting
  • Confident, execution focused, team oriented, with an ability to thrive in an entrepreneurial environment
  • Multitask and able to adjust workload based on shifting priorities

Apply for this Job

* Required

U.S. Equal Opportunity Employment Information (Completion is voluntary)

Individuals seeking employment at Omega Therapeutics are considered without regards to race, color, religion, national origin, age, sex, marital status, ancestry, physical or mental disability, veteran status, gender identity, or sexual orientation. You are being given the opportunity to provide the following information in order to help us comply with federal and state Equal Employment Opportunity/Affirmative Action record keeping, reporting, and other legal requirements.

Completion of the form is entirely voluntary. Whatever your decision, it will not be considered in the hiring process or thereafter. Any information that you do provide will be recorded and maintained in a confidential file.

Race & Ethnicity Definitions

If you believe you belong to any of the categories of protected veterans listed below, please indicate by making the appropriate selection. As a government contractor subject to Vietnam Era Veterans Readjustment Assistance Act (VEVRAA), we request this information in order to measure the effectiveness of the outreach and positive recruitment efforts we undertake pursuant to VEVRAA. Classification of protected categories is as follows:

A "disabled veteran" is one of the following: a veteran of the U.S. military, ground, naval or air service who is entitled to compensation (or who but for the receipt of military retired pay would be entitled to compensation) under laws administered by the Secretary of Veterans Affairs; or a person who was discharged or released from active duty because of a service-connected disability.

A "recently separated veteran" means any veteran during the three-year period beginning on the date of such veteran's discharge or release from active duty in the U.S. military, ground, naval, or air service.

An "active duty wartime or campaign badge veteran" means a veteran who served on active duty in the U.S. military, ground, naval or air service during a war, or in a campaign or expedition for which a campaign badge has been authorized under the laws administered by the Department of Defense.

An "Armed forces service medal veteran" means a veteran who, while serving on active duty in the U.S. military, ground, naval or air service, participated in a United States military operation for which an Armed Forces service medal was awarded pursuant to Executive Order 12985.

Form CC-305

OMB Control Number 1250-0005

Expires 05/31/2023

Voluntary Self-Identification of Disability

Why are you being asked to complete this form?

We are a federal contractor or subcontractor required by law to provide equal employment opportunity to qualified people with disabilities. We are also required to measure our progress toward having at least 7% of our workforce be individuals with disabilities. To do this, we must ask applicants and employees if they have a disability or have ever had a disability. Because a person may become disabled at any time, we ask all of our employees to update their information at least every five years.

Identifying yourself as an individual with a disability is voluntary, and we hope that you will choose to do so. Your answer will be maintained confidentially and not be seen by selecting officials or anyone else involved in making personnel decisions. Completing the form will not negatively impact you in any way, regardless of whether you have self-identified in the past. For more information about this form or the equal employment obligations of federal contractors under Section 503 of the Rehabilitation Act, visit the U.S. Department of Labor’s Office of Federal Contract Compliance Programs (OFCCP) website at www.dol.gov/ofccp.

How do you know if you have a disability?

You are considered to have a disability if you have a physical or mental impairment or medical condition that substantially limits a major life activity, or if you have a history or record of such an impairment or medical condition.

Disabilities include, but are not limited to:

  • Autism
  • Autoimmune disorder, for example, lupus, fibromyalgia, rheumatoid arthritis, or HIV/AIDS
  • Blind or low vision
  • Cancer
  • Cardiovascular or heart disease
  • Celiac disease
  • Cerebral palsy
  • Deaf or hard of hearing
  • Depression or anxiety
  • Diabetes
  • Epilepsy
  • Gastrointestinal disorders, for example, Crohn's Disease, or irritable bowel syndrome
  • Intellectual disability
  • Missing limbs or partially missing limbs
  • Nervous system condition for example, migraine headaches, Parkinson’s disease, or Multiple sclerosis (MS)
  • Psychiatric condition, for example, bipolar disorder, schizophrenia, PTSD, or major depression

1Section 503 of the Rehabilitation Act of 1973, as amended. For more information about this form or the equal employment obligations of Federal contractors, visit the U.S. Department of Labor's Office of Federal Contract Compliance Programs (OFCCP) website at www.dol.gov/ofccp.

PUBLIC BURDEN STATEMENT: According to the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless such collection displays a valid OMB control number. This survey should take about 5 minutes to complete.